Kumar Pramod, Krishna Pradeep, Maidur Rohit, Chandrashekhar Naveen, Raghavaiah Suresh
Department of Hepatology, Gleneagles BGS Hospital, Bengaluru, India.
Department of Liver Transplantation Surgery, Gleneagles BGS Hospital, Bengaluru, India.
J Liver Cancer. 2025 Mar;25(1):134-137. doi: 10.17998/jlc.2024.09.26. Epub 2024 Nov 5.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.
伴有门静脉癌栓（PVTT）的肝细胞癌（HCC）预后较差。阿替利珠单抗联合贝伐珠单抗（阿替利珠单抗-贝伐珠单抗）是推荐的姑息治疗方案，根据改良实体瘤疗效评价标准（mRECIST），约10%的患者可能会出现完全缓解（CR）。治疗持续至疾病进展或出现不可接受的副作用。长期持续治疗可能会导致潜在毒性和巨大的经济负担，因此提前终止治疗是一个可行的选择。本报告描述了3例HCC合并PVTT患者在停用阿替利珠单抗-贝伐珠单抗治疗后出现的持久CR。
